The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Early recognition and diagnosis of BPDCN: skin biopsy, markers, and specialist referral
Andrew Lane, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, emphasizes the importance of early recognition of blastic plasmacytoid dendritic cell neoplasm (BPDCN) by biopsy of suspicious skin lesions using appropriate markers. He underscores the importance of rapid referral to specialized centers for confirmation and treatment planning. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
